IDAHO VETERANS RESEARCH & EDUCATIO… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2011

Legal Domicile

Principal Officer

MARGARET K ALDAPE

Phone

2084221000

Tax Period

2024-10-01 to 2025-09-30

IDAHO VETERANS RESEARCH & EDUCATION FOUNDATION, founded in 2011, is a community nonprofit in the Health Care sector that reported $1.1M in total revenue in fiscal year 2024.

Mission

TO ADVANCE THE RESEARCH AND EDUCATION MISSION OF THE DEPARTMENT OF VETERANS AFFAIRS AND SPECIFICALLY THE BOISE VA MEDICAL CENTER THROUGH THE SUPPORT OF RESEARCH AND EDUCATION RELATED ACTIVITIES.

Program Service Accomplishments

Program 1

Expenses: $944,609 Revenue: $830,983

EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF...

EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF HOBDEY DRP 3)NIH R21 - ROLE OF MIR-181A-5P IN ADENOVIRUS 14P1 INDUCED ACUTE LUNG INJURY 4)NIH RO3 - DEVELOPMENT OF ANTIBODIES TO SPECIFIC CELL SURFACE MARKERS TO ASSESS MACROPHAGE POLARIZATION DURING ADENOVIRUS 14 AND 14P1 INFECTION IN THE SYRIAN HAMSTER. 5) NIH (U OF PITTSBURGH SUB-AWARD) - MACS/WIHS CCS KUNISAKI 6)PCORI (SIBCR SUB-AWARD) - FUNCTIONAL IMPROVEMENT IN OSA AND COPD WITH A TELEHEALTH LIFESTYLE AND EXERCISE INTERVENTION (FOCUSED) 7)PARATEK PHARMACEUTICALS - INVESTIGATING THE ANTI-INFLAMMATORY ACTIVITIES OF OMADACYCLINE 8)ALTO PHARMACEUTICALS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER. 9)JANSSEN RESEARCH & DEVELOPMENT - MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA 10)FERRING PHARMACEUTICALS - A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN- LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) 11)STABILITY BIOLOGICS - A MULTICENTER, PROSPECTIVE, RANDOMIZED CONTROLLED MODIFIED MULTI-PLATFORM (MATRIARCH) TRIAL EVALUATING SEVERAL CELLULAR, ACELLULAR, AND MATRIX-LIKE PRODUCTS (CAMPS) AND STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN THE MANAGEMENT OF NONHEALING DIABETIC FOOT AND VENOUS LEG ULCERS

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $299,779

Program Service Revenue $830,983

Investment Income $8,338

Other Revenue $252

TOTAL REVENUE $1,139,352

Expense Breakdown

Grants Paid $0

Salaries & Benefits $762,180

Fundraising Expenses $0

Program Expenses $944,609

Other Expenses $413,988

TOTAL EXPENSES $1,176,168

Year-over-Year Comparison

	2024	2023	Change
Revenue	$1,139,352	$1,118,208	+0.0%
Expenses	$1,176,168	$1,132,531	+0.0%
Net Income	$-36,816	$-14,323	+1.6%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$163,617

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MARGARET K ALDAPE	EXECUTIVE DI	40.00	Officer	$85,606	$0	$85,606
MICAH ROOS	CFO	40.00	Officer	$78,011	$0	$78,011
MARTIN BLAIR	DIRECTOR	10.00	Director	$0	$0	$0
MARGARET DOUCETTE	PRESIDENT	10.00	Officer Director	$0	$0	$0
AMBER FISHER	DIRECTOR	10.00	Director	$0	$0	$0
ANDREW WILPER	VICE PRESIDE	10.00	Officer Director	$0	$0	$0
DAVID WOOD	CHAIRMAN	10.00	Officer Director	$0	$0	$0
ROBERT WOOD	SECRETARY	10.00	Director	$0	$0	$0
JANET HINES	TREASURER	10.00	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$1,139,352	$1,176,168	$626,538	$-36,816
2024	$1,118,208	$1,132,531	$661,046	$-14,323
2023	$717,830	$908,074	$653,845	$-190,244
2022	$1,247,615	$1,373,828	$840,037	$-126,213
2021	$1,735,785	$1,703,177	$1,004,381	$32,608
2020	$1,967,846	$1,953,647	$1,329,626	$14,199
2019	$2,139,409	$2,020,771	$1,214,936	$118,638
2018	$2,460,238	$2,285,280	$1,129,598	$174,958

IDAHO VETERANS RESEARCH & EDUCATION FOUNDATION